Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis
- 15 July 2008
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 149 (2) , 123-134
Abstract
Despite the increasing prevalence of drug-resistant tuberculosis, most low- and middle-income countries use standardized regimens, without assessment of drug susceptibility. To perform a systematic review and meta-analysis of the effect of initial drug resistance and treatment regimen on tuberculosis treatment outcomes. PubMed, the Cochrane Central Database of Clinical Trials, and EMBASE were searched for studies published in English from 1965 to June 2007. Additional studies were identified from cited references. Randomized, controlled trials and cohort studies of standardized treatment of previously untreated patients with culture-confirmed pulmonary tuberculosis. Drug-susceptibility testing was done on pretreatment isolates from all patients and from patients with treatment failure or relapse. Two authors reviewed the studies for methods, initial drug resistance, treatment regimens, and outcomes. Pooled cumulative incidences were computed with random-effects meta-analyses. Association between risk factors and outcomes were determined by using stratified analyses. The cumulative incidence of acquired drug resistance with initially pan-sensitive strains was 0.8% (95% CI, 0.5% to 1.0%) compared with 6% (CI, 4% to 8%) with initially single drug–resistant strains and 14% (CI, 9% to 20%) with initially polydrug-resistant strains. Failure and relapse were most strongly associated with initial drug resistance. Failure was also associated with shorter duration of rifampin therapy and nonuse of streptomycin, whereas the rate of relapse was higher with shorter duration of rifampin therapy and nonuse of pyrazinamide. Few studies included HIV-infected persons, and treatment outcomes were pooled despite considerable heterogeneity. Treatment outcomes were substantially worse in the presence of initial drug resistance, which has important implications in resource-limited settings in which drug resistance is prevalent.Keywords
This publication has 44 references indexed in Scilit:
- Faculty Opinions recommendation of Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis.2007
- Global Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2006
- Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs--Worldwide, 2000-20042006
- The Effect of Initial Drug Resistance on Treatment Response and Acquired Drug Resistance during Standardized Short-Course Chemotherapy for TuberculosisClinical Infectious Diseases, 2004
- Risk Factors for Relapse and Acquired Rifamycin Resistance after Directly Observed Tuberculosis Treatment: A Comparison by HIV Serostatus and Rifamycin UseClinical Infectious Diseases, 2004
- Tuberculosis treatment failure and drug resistance—same strain or reinfection?Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000
- Human Immunodeficiency Virus and the Outcome of Treatment for New and Recurrent Pulmonary Tuberculosis in African PatientsAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Meta-analysis: formulating, evaluating, combining, and reportingStatistics in Medicine, 1999
- A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: A twice-weekly, directly observed, and cost-effective regimen: Cohn DL, Catlin BJ, Peterson KL, et al: Ann Intern Med 112:407–415, 1990Infectious Diseases Newsletter, 1990
- SHORT-COURSE (6-MONTH) COOPERATIVE TUBERCULOSIS STUDY IN POLAND - RESULTS 30 MONTHS AFTER COMPLETION OF TREATMENT1981